A durable bioprosthetic vascular graft is badly needed for vascular bypass surgery. For peripheral vascular surgery, there is essentially no viable alternative to an autogenous venous conduit to bypass leg arteries. In part, the challenges to establishing an endothelialized graft have been gaps in our understanding of how specific growth factors and matrix proteins interact with each other and modulate cellular responses. Heparins are known to modulate growth responses, but heparin's effects have been confusing and contradictory, due to the heterogeneity of heparin's structure and its diverse interactions. We have discovered that vascular endothelial growth factor (VEGF) and fibronectin (Fn) have a unique and dedicated biologic partnership. Fn binds VEGF like no other matrix protein, and Fn significantly enhances the endothelial migration and proliferation mediated by VEGF. Their cognate receptors, alpha5beta1 and VEGFR2 also work in synergy. We have also demonstrated that VEGF-Fn complexes uniquely enhance the differentiation of endothelial progenitor cells (EPC) into the endothelial line. Our goals are: 1) Elucidate the mechanisms underlying Fn promotion of VEGF activity, 2) Define the structure-activity relations of heparin's modulation of VEGF-VEGFR2 binding, 3) Define and develop recombinant fibronectin constructs and heparin oligosaccharides that when combined with VEGF and EPC will enhance endothelialization of a porous vascular graft, by capillary in growth and the differentiation of EPC. Using recombinant Fn constructs, we will identify the Fn domains that are key to promoting VEGF mitogenic effects. Using structurally defined synthetic oligosaccharides, and novel surface plasmon resonance technology we will identify the optimal size and structure of heparin that promotes VEGF binding to its receptor VEGFR2. In an animal model of peripheral artery bypass grafting that closely resembles the human condition, we will test these constructs and cells for their ability to promote the growth of a stable endothelial lining.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL079182-02
Application #
7081322
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Lundberg, Martha
Project Start
2005-07-01
Project End
2009-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
2
Fiscal Year
2006
Total Cost
$324,557
Indirect Cost
Name
University of Washington
Department
Surgery
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Yagi, Mayumi; Murray, Jacqueline; Strand, Kurt et al. (2012) Heparin modulates the conformation and signaling of platelet integrin ?IIb?3. Thromb Res 129:743-9
Stenzel, Denise; Lundkvist, Andrea; Sauvaget, Dominique et al. (2011) Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development 138:4451-63
Wijelath, Errol; Kohler, Ted R; Murray, Jacqueline et al. (2010) Enhancement of capillary and cellular ingrowth in ePTFE implants with a proangiogenic recombinant construct derived from fibronectin. J Biomed Mater Res A 95:641-8
Wijelath, Errol; Namekata, Mayumi; Murray, Jacqueline et al. (2010) Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J Cell Biochem 111:461-8
Saito, Akihiro; Wakao, Masahiro; Deguchi, Hiroshi et al. (2010) Towards the assembly of heparin and heparan sulfate oligosaccharide libraries: efficient synthesis of uronic acid and disaccharide building blocks. Tetrahedron 66:3951-3962
Sato, Masaki; Ito, Yuji; Arima, Naomichi et al. (2009) High-sensitivity analysis of naturally occurring sugar chains, using a novel fluorescent linker molecule. J Biochem 146:33-41
Wakao, Masahiro; Saito, Akihiro; Ohishi, Koh et al. (2008) Sugar Chips immobilized with synthetic sulfated disaccharides of heparin/heparan sulfate partial structure. Bioorg Med Chem Lett 18:2499-504
Wijelath, Errol S; Rahman, Salman; Namekata, Mayumi et al. (2006) Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 99:853-60